奥克雷利祖马布诱导的大肠炎:VigiBase不成比例分析,病例报告和文献综述
Audrey Fresse1, Christophe Hommel2, Nadine Petitpain1
1Regional Pharmacovigilance Center of Nancy, Pharmaco-toxicology Department, University Hospital of Nancy, Vandoeuvre-lès-Nancy, France.
用于多发性硬化症的ocrelizumab可能与大肠炎有关. 对药物不良反应和文献的分析表明,这种抗CD20抗体具有潜在的安全信号.
科学领域:
- 药物监督 药物监督 药物监督
- 免疫学 免疫学 免疫学
- 胃肠病学 胃肠病学
背景情况:
- 奥克雷利祖马布是一种针对多发性硬化症的向治疗方法.
- 营销后监测发现了与ocrelizumab相关的结肠炎病例.
- 了解这种潜在的不良药物反应对于患者的安全至关重要.
研究的目的:
- 为了调查ocrelizumab和大肠炎之间的关联.
- 评估大肠炎作为ocrelizumab的潜在不良药物反应 (ADR).
- 分析药监数据和文献以检测安全信号.
主要方法:
- 对ocrelizumab诱导的大肠炎的VigiBase数据进行描述性和不成比例分析.
- 报告病例的综合文献审查.
- 来自卢森堡药监中心的病例系列描述.
主要成果:
- 在VigiBase分析中,发现了400例ocrelizumab诱导的大肠炎病例,其中79%是严重的,中位数发病17个月.
- 对于"结肠炎"和相关术语,包括微观结肠炎和免疫媒介性肠结肠炎,存在显著的不成比例.
- 文献审查发现24例病例报告 (36名患者),中位数发病时间为18个月;两名患者在再次暴露后复发.
结论:
- 临床病例,文献综述和VigiBase数据表明,ocrelizumab诱导的大肠炎的潜在安全信号.
- 这些发现凸显了在接受ocrelizumab治疗的患者中监测胃肠道不良事件的重要性.
- 可能需要进一步的研究来阐明这种ADR的机制和发生率.
更多相关视频
07:38Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
Published on: September 13, 2016
06:24Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer
Published on: October 13, 2023
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
